Positive Phase I Results Reported for DURECT's Second Abuse-Resistant Opioid Pain Medicine.
CUPERTINO, Calif., Nov. 30 /PRNewswire-FirstCall/ -- DURECT Corporation today reported positive results from a Phase I clinical trial evaluating an abuse-resistant opioid pain drug candidate based on DURECT's patented ORADUR(TM) technology. The event was announced on November 29 by Pain Therapeutics, Inc., DURECT's licensee of the rights to this...

Pain Therapeutics Initiates Phase III Study With Oxytrex(TM).
-- Study Will Enroll Patients Prone to Opioid Dependence -- SOUTH SAN FRANCISCO, Calif., Dec. 13 /PRNewswire-FirstCall/ -- Pain Therapeutics, Inc. today announced the initiation of a Phase III study with Oxytrex, an investigational drug. Oxytrex is a unique oral painkiller for patients who suffer from persistent...

Cast a wide net with chronic pain.
Chronic pain cuts wide. One out of every five people lives with some sort of chronic pain. Of that 20%, one-third are not able or are only minimally able to maintain an independent lifestyle because of it, according to the International Association for the Study of Pain. ...

Managing chronic pain: gaps problematic in primary care.
SAN ANTONIO -- Clinicians in the field vary greatly in their comfort and confidence in assessing and managing chronic pain, according to a survey presented at a poster session at the annual meeting of the American Pain Society. "Primary care providers are uncomfortable in treating pain and...

Behavioral conceptualization and treatment for chronic pain.
Abstract The current article offers a behavioral conceptualization for clinical pain, reviews the empirical evidence supporting this behavioral model, summarizes evidence-based behavioral treatments for chronic pain and supporting science, outlines treatment application limits, and summarizes research needs. Clinical pain is defined as an interacting cluster of overt,...

New Leadership, New Vision Mark New Threshold for Pain Treatment Center at Pittsburgh's Ohio Valley General Hospital.
Hospital competes and wins when highly recruited doctor agrees to lead program KENNEDY TOWNSHIP, Pa., Nov. 3 /PRNewswire/ -- David A. Provenzano, M.D. has accepted the position of Medical Director at the Hospital's new Pain Treatment Center in Robinson Township. A recent fellow at the prestigious Dartmouth-Hitchcock...

Study Shows Pregabalin Effective in Difficult-to-Treat Nerve Pain.
SYDNEY, Australia, November 28 /PRNewswire/ -- - Results Offer Hope to Patients With Excruciating Chronic Pain Findings from a new study published today in the journal Neurology demonstrate that the oral medication pregabalin is significantly effective in relieving central neuropathic (nerve) pain and improves pain-related sleep disturbance...

Cancer pain needs vary among African Americans.
WASHINGTON -- African American cancer patients are heterogeneous in their need for pain medication, Salimah Meghani, Ph.D., said at a meeting sponsored by the Department of Health and Human Services and the Office of Minority Health. Dr. Meghani interviewed 36 self-identified African American cancer patients from three...

Simple measures may reduce patients' postoperative pain.
VANCOUVER, B.C. -- Simple measures taken at the time of ambulatory surgery, such as the use of clonidine, can significantly reduce patients' postprocedure pain, Dr. Scott S. Reuben said at the annual meeting of the American Pain Society. On a scientific front, "there has been an explosion...

Boston Scientific Receives CE Mark for Artisan(TM) Surgical Lead for Use With Neurostimulation Device to Treat Chronic Pain.
Innovative Technology Makes Precision(TM) Spinal Cord Stimulator Accessible to More Patients NATICK, Mass., Nov. 3 /PRNewswire-FirstCall/ -- Boston Scientific Corporation today announced that it has received the European CE Mark for its new Artisan(TM) 2x8 Surgical Lead for use with the Precision(TM) Spinal Cord Stimulation (SCS) System....